Market Research Logo

Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight’s ‘Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AKI in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Kidney Injury (AKI) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Acute Kidney Injury (AKI) - Disease Understanding and Treatment Algorithm

The DelveInsight Acute Kidney Injury (AKI) market report gives the thorough understanding of the Acute Kidney Injury by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Kidney Injury in the US, Europe, and Japan.

Acute Kidney Injury Epidemiology

The Acute Kidney Injury (AKI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, discharge diagnosed cases, stage-wise discharge diagnosed cases, risk factor associated AKI cases and renal transplantation associated delayed graft function cases) scenario of Acute Kidney Injury (AKI) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, total incident population of Acute Kidney Injury (AKI) in 7 major markets was found to be 1,516,635 in 2016. 

Acute Kidney Injury Drug Chapters

This segment of the Acute Kidney Injury report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently there are no targeted pharmacotherapies approved for the treatment of AKI. At present, the therapeutic market size of acute kidney injury is mainly accounted by use of Renal Replacement Therapy (RRT) and off-label drugs which includes various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Detailed chapter for upcoming therapies like BB3 (Angion Biomedica), QPI1002 (Quark Pharmaceutical), recAP (AM Pharma), SBI101 (Sentien Biotechnologies), Reltecimod (Ato Bio), THR-184 (Thrasos Therapeutics) (EA230 (Exponential Biotherapies), Simdax (Orion Pharma), and bRESCAP (Alloksys) have been covered in the report.

Acute Kidney Injury Market Outlook

The Acute Kidney Injury market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Acute Kidney Injury in 7MM was found to be USD 4.3 billion in 2016 and is expected to increase at a CAGR of XX% from 2016-2027.

Acute Kidney injury Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Kidney Injury Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Acute Kidney Injury Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Acute Kidney Injury Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Kidney Injury market
• Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury market
• To understand the future market competition in the Acute Kidney Injury market.


1. Key Insights
2. Acute Kidney Injury Market: Overview at a Glance
2.1. Market Share Distribution of AKI in 2017
2.2. Market Share Distribution of AKI in 2027
3. Acute Kidney Injury (AKI): Disease Background and Overview
3.1. Introduction
3.2. Symptoms
3.3. Types of Acute Kidney Injury
3.4. Stages Classification
3.5. Risk Factors
3.6. Etiology
3.7. Pathophysiology
3.8. Biomarkers
3.9. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Incident Patient Population of AKI
4.3. 7MM Total Discharge Diagnosed Population of AKI
5. Country Wise-Epidemiology of Acute Kidney Injury
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Incident Cases of Acute Kidney Injury in the US
5.1.3. Discharge Diagnosed Cases of Acute Kidney Injury in the US
5.1.4. Stage-Wise Discharged Diagnosed Cases of Acute Kidney Injury in the US
5.1.5. Risk Factor Associated Acute Kidney Injury Cases in the US
5.1.6. Renal Transplantation Associated Delayed Graft Function Cases in the US
5.2. EU5
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Incident Cases of Acute Kidney Injury in Germany
5.3.2. Discharge Diagnosed Cases of Acute Kidney Injury in Germany
5.3.3. Stage-Wise Discharged Diagnosed Cases of Acute Kidney Injury in Germany
5.3.4. Risk Factor Associated Acute Kidney Injury Cases in Germany
5.3.5. Renal Transplantation Associated Delayed Graft Function Cases in Germany
5.4. France
5.4.1. Incident Cases of Acute Kidney Injury in France
5.4.2. Discharge Diagnosed Cases of Acute Kidney Injury in France
5.4.3. Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury in France
5.4.4. Risk Factor Associated Acute Kidney Injury Cases in France
5.4.5. Renal Transplantation Associated Delayed Graft Function Cases in France
5.5. Italy
5.5.1. Incident Cases of Acute Kidney Injury in Italy
5.5.2. Discharge Diagnosed Cases of Acute Kidney Injury in Italy
5.5.3. Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury in Italy
5.5.4. Risk Factor Associated Acute Kidney Injury Cases in Italy
5.5.5. Renal Transplantation Associated Delayed Graft Function Cases in Italy
5.6. Spain
5.6.1. Incident Cases of Acute Kidney Injury in Spain
5.6.2. Discharge Diagnosed Cases of Acute Kidney Injury in Spain
5.6.3. Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury in Spain
5.6.4. Risk Factor Associated Acute Kidney Injury Cases in Spain
5.6.5. Renal Transplantation Associated Delayed Graft Function Cases in Spain
5.7. United Kingdom
5.7.1. Incident Cases of Acute Kidney Injury in the UK
5.7.2. Discharge Diagnosed Incident Cases of Acute Kidney Injury in the UK
5.7.3. Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury in the UK
5.7.4. Risk Factor Associated Acute Kidney Injury Cases in the UK
5.7.5. Renal Transplantation Associated Delayed Graft Function Cases in the UK
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Incident Cases of Acute Kidney Injury in Japan
5.8.3. Discharge Diagnosed Cases of Acute Kidney Injury Japan
5.8.4. Stage-Wise Discharge Diagnosed Cases of Acute Kidney Injury in Japan
5.8.5. Risk Factor Associated Acute Kidney Injury Cases in Japan
5.8.6. Renal Transplantation Associated Delayed Graft Function Cases in Japan
6. Current Treatment Practices
6.1. Treatment and Prevention
7. Unmet Needs
8. Emerging Therapies
8.1. Key cross competition- Emerging Therapies
8.2. EA-230: Exponential Biotherapies
8.2.1. Clinical Development
8.2.2. Clinical Trials Information
8.2.3. Safety and Efficacy
8.2.4. Product Profile
8.3. Zemiglo: LG Life Sciences
8.3.1. Clinical Development
8.3.2. Clinical Trials Information
8.3.3. Safety and Efficacy
8.3.4. Product Profile
8.4. bRESCAP: Alloksys
8.4.1. Other Developmental Activities
8.4.2. Clinical Development
8.4.3. Clinical Trials Information
8.4.4. Product Profile
8.5. BB3: Angion Biomedica
8.5.1. Other Developmental Activities
8.5.2. Clinical Trials Information
8.5.3. Safety and Efficacy
8.5.4. Product Profile
8.6. QPI-1002: Quark Pharmaceuticals
8.6.1. Other Developmental Activities
8.6.2. Clinical Development
8.6.3. Clinical Trial Information
8.6.4. Safety and Efficacy
8.6.5. Advantages and Disadvantages
8.6.6. Product Profile
8.7. recAP: AM Pharma
8.7.1. Other Developmental Activities
8.7.2. Clinical Development
8.7.3. Clinical Trial Information
8.7.4. Safety and Efficacy
8.7.5. Product Profile
8.8. THR-184: Thrasos Therapeutics
8.8.1. Other Developmental Activities
8.8.2. Clinical Development
8.8.3. Clinical Trial Information
8.8.4. Safety and Efficacy
8.8.5. Product Profile
8.9. Reltecimod: AtoxBio
8.9.1. Other Developmental Activities
8.9.2. Clinical Development
8.9.3. Clinical Trial Information
8.9.4. Safety and Efficacy
8.9.5. Product Profile
9. Acute Kidney Injury: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of AKI in 7MM
10. Market Outlook by Country
10.1. United States Market Outlook
10.2. United States Market Size
10.2.1. Total Market size of AKI
10.2.2. Market Size by Therapies
10.3. EU-5 Countries: Market Outlook
10.4. Germany Market Size
10.4.1. Total Market size of AKI
10.4.2. Market Size by Therapies
10.5. France Market Size
10.5.1. Total Market size of AKI
10.5.2. Market Size by Therapies
10.6. Italy Market Size
10.6.1. Total Market size of AKI
10.6.2. Market Size by Therapies
10.7. United Kingdom Market Size
10.7.1. Total Market size of AKI
10.7.2. Market Size by Therapies
10.8. Spain Market Size
10.8.1. Total Market size of AKI
10.8.2. Market Size by Therapies
10.9. Japan: Market Outlook
10.10. Japan Market Size
10.10.1. Total Market size of AKI
10.10.2. Market Size by Therapies
11. Trends in Cost of Therapies in Acute Kidney Injury
12. Market Drivers
13. Market Barriers
14. DelveInsight Capabilities
15. Appendix
15.1. Report Methodology
16. Disclaimer
17. About DelveInsight
List of Tables and Figures
Table 1: Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification
Table 2: KDIGO Criteria
Table 3: Causes of AKI: Exposures and Susceptibilities for non-specific AKI
Table 4: Biomarkers of AKI
Table 5: RIFLE Criteria for AKI
Table 6: AKIN Criteria for AKI
Table 7: KDIGO Criteria for AKI
Table 8: Total Incident Population of AKI in the 7MM (2016-2027)
Table 9: Total Discharge Diagnosed Population of AKI in the 7MM (2016-2027)
Table 10: Incident Cases of AKI in the US (2016-2027)
Table 11: Discharge Diagnosed Cases of AKI in the US (2016-2027)
Table 12: Stage Wise Discharged Diagnosed Cases of AKI in the US (2016-2027)
Table 13: Risk Factor Associated AKI Cases in the US (2016-2027)
Table 14: Renal Transplantation Associated Delayed Graft Function Cases in the US (2016-2027)
Table 15: Incident Cases of AKI in Germany (2016-2027)
Table 16: Discharge Diagnosed Cases of AKI in Germany (2016-2027)
Table 17: Stage-Wise Incident Cases of AKI in Germany (2016-2027)
Table 18: Risk Factor Associated Cases of AKI in Germany (2016-2027)
Table 19: Renal Transplantation Associated Delayed Graft Function Cases in Germany (2016- 2027)
Table 20: Incident Cases of AKI in France (2016-2027)
Table 21: Discharge Diagnosed Cases of AKI in France (2016-2027)
Table 22: Stage-Wise Discharge Diagnosed Cases of AKI in France (2016-2027)
Table 23: Risk Factor Associated AKI Cases in France (2016-2027)
Table 24: Renal Transplantation Associated Delayed Graft Function Cases in France (2016- 2027)
Table 25: Incident Cases of AKI in Italy (2016-2027)
Table 26: Discharge Diagnosed Cases of AKI in Italy (2016-2027)
Table 27: Stage-Wise Discharge Diagnosed Cases of AKI in Italy (2016-2027)
Table 28: Risk Factor Associated AKI Cases in Italy (2016-2027)
Table 29: Renal Transplantation Associated Delayed Graft Function Cases in Italy (2016-2027)
Table 30: Incident Cases of AKI in Spain (2016-2027)
Table 31: Discharge Diagnosed Cases of AKI in Spain (2016-2027)
Table 32: Stage-Wise Discharge Diagnosed Cases of AKI in Spain (2016-2027)
Table 33: Risk Factor Associated AKI Cases in Spain (2016-2027)
Table 34: Renal Transplantation Associated Delayed Graft Function Cases in Spain (2016-2027)
Table 35: Incident Cases of AKI in the UK (2016-2027)
Table 36: Discharge Diagnosed Cases of AKI in the UK (2016-2027)
Table 37: Stage-Wise Discharge Diagnosed Cases of AKI in the UK (2016-2027)
Table 38: Risk Factor Associated AKI Cases in the UK (2016-2027)
Table 39: Renal Transplantation Associated Delayed Graft Function Cases in the UK (2016-2027)
Table 40: Incident Cases of AKI in Japan (2016-2027)
Table 41: Discharge Diagnosed Cases of AKI in Japan (2016-2027)
Table 42: Stage-Wise Discharge Diagnosed Cases of AKI in Japan (2016-2027)
Table 43: Risk Factor Associated AKI Cases in Japan (2016-2027)
Table 44: Renal Transplantation Associated Delayed Graft Function Cases in Japan (2016-2027)
Table 45: Renal Replacement Therapy (RRT) Modalities for AKI
Table 46: Key Cross – Emerging Therapies
Table 47: EA-230, Clinical Trials Description, 2017
Table 48: bRESCAP, Clinical Trial Description, 2017
Table 49: BB3, Clinical Trial Description, 2017
Table 50: QPI-1002, Clinical Trial Description, 2017
Table 51: recAP, Clinical Trial Description, 2017
Table 52: THR-184, Clinical Trial Description, 2017
Table 53: Reltecimod, Clinical Trial Description, 2017
Table 54: 7 Major Market Size of AKI in USD Billion (2016-2027)
Table 55: Market Size of AKI in the US, USD Billion (2016-2027)
Table 56: Market size of AKI by therapies in the US, in USD Million (2016-2027)
Table 57: Market Size of AKI in Germany, USD Billion (2016-2027)
Table 58: Market size of AKI by therapies in Germany, in USD Million (2016-2027)
Table 59: Market Size of AKI in France, USD Billion (2016-2027)
Table 60: Market size of AKI by therapies in France, in USD Million (2016-2027)
Table 61: Market Size of AKI in Italy, USD Billion (2016-2027)
Table 62: Market size of AKI by therapies in Italy, in USD Million (2016-2027)
Table 63: Market Size of AKI in the UK, USD Billion (2016-2027)
Table 64: Market size of AKI by therapies in the UK, in USD Million (2016-2027)
Table 65: Market Size of AKI in Spain, USD Billion (2016-2027)
Table 66: Market size of AKI by therapies in Spain, in USD Million (2016-2027)
Table 67: Market Size of AKI in Japan, USD Billion (2016-2027)
Table 68: Market size of AKI by therapies in Japan, in USD Million (2016-2027)
Table 69: Trends in Cost of Therapies in Acute Kidney Injury
Figure 1: Types of Acute Kidney Injury
Figure 2: Risk factors associated with Acute Kidney Injury
Figure 3: Common Causes of AKI
Figure 4: Pathophysiology of AKI
Figure 5: Biomarkers of AKI
Figure 6: Total Incident Patient Population of AKI in the 7MM (2016-2027)
Figure 7: Total Discharge Diagnosed Population of AKI in the 7MM (2016-2027)
Figure 8: Incident Cases of AKI in the US (2016-2027)
Figure 9: Discharge Diagnosed Cases of AKI in the US (2016-2027)
Figure 10: Stage Wise Discharged Diagnosed Cases of AKI in the US (2016-2027)
Figure 11: Risk Factor Associated AKI Cases in the US (2016-2027)
Figure 12: Renal Transplantation Associated Delayed Graft Function Cases in the US (2016-2027)
Figure 13: Incident Cases of AKI in Germany (2016-2027)
Figure 14: Discharge Diagnosed Cases of AKI in Germany (2016-2027)
Figure 15: Stage-Wise Incident Cases of AKI in Germany (2016-2027)
Figure 16: Risk Factor Associated AKI Cases in Germany (2016-2027)
Figure 17: Renal Transplantation Associated Delayed Graft Function Cases in Germany (2016-2027)
Figure 18: Incident Cases of AKI in France (2016-2027)
Figure 19: Discharge Diagnosed Cases of AKI in France (2016-2027)
Figure 20: Stage-Wise Discharge Diagnosed Cases of AKI in France (2016-2027)
Figure 21: Risk Factor Associated AKI Cases in France (2016-2027)
Figure 22: Renal Transplantation Associated Delayed Graft Function Cases in France (2016-2027)
Figure 23: Incident Cases of AKI in Italy (2016-2027)
Figure 24: Discharge Diagnosed Cases of AKI in Italy (2016-2027)
Figure 25: Stage-Wise Discharge Diagnosed Cases of AKI in Italy (2016-2027)
Figure 26: Risk Factor Associated AKI Cases in Italy (2016-2027)
Figure 27: Renal Transplantation Associated Delayed Graft Function Cases in Italy (2016-2027)
Figure 28: Incident Cases of AKI in Spain (2016-2027)
Figure 29: Discharge Diagnosed Cases of AKI in Spain 2016-2027)
Figure 30: Stage-Wise Discharge Diagnosed Cases of AKI in Spain (2016-2027)
Figure 31: Risk Factor Associated AKI Cases in Spain (2016-2027)
Figure 32: Renal Transplantation Associated Delayed Graft Function Cases in Spain (2016-2027)
Figure 33: Incident Cases of AKI in the UK (2016-2027)
Figure 34: Discharge Diagnosed Cases of AKI in the UK (2016-2027)
Figure 35: Stage-Wise Discharge Diagnosed Cases of AKI the UK (2016-2027)
Figure 36: Risk Factor Associated AKI Cases in the UK (2016-2027)
Figure 37: Renal Transplantation Associated Delayed Graft Function Cases in the UK (2016-2027)
Figure 38: Incident Cases of AKI in Japan (2016-2027)
Figure 39: Discharge Diagnosed Incident Cases of AKI in Japan (2016-2027)
Figure 40: Stage-Wise Discharge Diagnosed Cases of AKI in Japan (2016-2027)
Figure 41: Risk Factor Associated AKI Cases in Japan (2016-2027)
Figure 42: Renal Transplantation Associated Delayed Graft Function Cases in Japan (2016-2027)
Figure 43: Global Mortality of AKI
Figure 44: Stage-based management of Acute Kidney Injury (AKI)
Figure 45: Unmet Needs for AKI
Figure 46: 7 Major Market Size of AKI in USD Billion (2016-2027)
Figure 47: Market Size of AKI in the US, USD Billion (2016-2027)
Figure 48: Market size of AKI by therapies in the US, in USD Million (2016-2027)
Figure 49: Market Size of AKI in Germany, USD Billion (2016-2027)
Figure 50: Market size of AKI by therapies in Germany, in USD Million (2016-2027)
Figure 51: Market Size of AKI in France, USD Billion (2016-2027)
Figure 52: Market size of AKI by therapies in France, in USD Million (2016-2027)
Figure 53: Market Size of AKI in Italy, USD Billion (2016-2027)
Figure 54: Market size of AKI by therapies in Italy, in USD Million (2016-2027)
Figure 55: Market Size of AKI in the UK, USD Billion (2016-2027)
Figure 56: Market size of AKI by therapies in the UK, in USD Million (2016-2027)
Figure 57: Market Size of AKI in Spain, USD Billion (2016-2027)
Figure 58: Market size of AKI by therapies in Spain, in USD Million (2016-2027)
Figure 59: Market Size of AKI in Japan, USD Billion (2016-2027)
Figure 60: Market size of AKI by therapies in Japan, in USD Million (2016-2027)
Figure 61: Market Drivers
Figure 62: Market Barriers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report